Inotiv Inc. logo

Inotiv Inc. (NOTV)

Market Closed
10 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
0. 02
+0.01
+63.6364%
$
2.79M Market Cap
- P/E Ratio
- Div Yield
424,576 Volume
-1.15 Eps
$ 0.01
Previous Close
Add Transaction
Day Range
0.01 0.02
Year Range
0.01 2.44
Want to track NOTV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NOTV closed Friday higher at $0.02, an increase of 63.6364% from Thursday's close, completing a monthly decrease of -93.7931% or -$0.27. Over the past 12 months, NOTV stock lost -96.8966%.
NOTV is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 0.5474%. On average, the company has surpassed earnings expectations by 0.1865%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

NOTV Chart

People also search for

Fuel Tech Inc.
$ 1.53
-1.2903%
SkyAI, Inc. Common Stock
$ 1.16
-2.521%
SEP Acquisition Corp.
$ -
-
CBAK Energy Technology Inc.
$ 0.54
+1.8868%
DarioHealth Corp.
$ 6.81
+0.6499%
Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript

Seekingalpha | 5 months ago
Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

Seekingalpha | 7 months ago
Inotiv, Inc. (NOTV) Q3 2025 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q3 2025 Earnings Call Transcript

Inotiv, Inc. (NASDAQ:NOTV ) Q3 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Beth A. Taylor - Senior VP of Finance & CFO John E.

Seekingalpha | 11 months ago

Inotiv Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
FFA
Fi3 FINANCIAL ADVISORS LLC Fi3 FINANCIAL ADVISORS LLC
65,710 $216,985 $1,182.78 -$215,802.22 -99.45%
Megan J. Lottier
Megan J. Lottier Rockwood Wealth Management, LLC
10,000 $17,000 $180 -$16,820 -98.94%
Annmarie Young
Annmarie Young KPP Advisory Services LLC
62,071 $110,503.9 $4,959.47 -$105,544.43 -95.51%
Ben Loeffler
Ben Loeffler ACORN CREEK CAPITAL LLC
10,000 $18,200 $799 -$17,401 -95.61%
MCM
Massar Capital Management LP Massar Capital Management LP
342,700 $679,367 $6,168.6 -$673,198.4 -99.09%

Inotiv Inc. (NOTV) FAQ

What is the stock price today?

The current price is $0.02.

On which exchange is it traded?

Inotiv Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is NOTV.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.79M.

Has Inotiv Inc. ever had a stock split?

No, there has never been a stock split.

Inotiv Inc. Profile

Professional Services Industry
Industrials Sector
Robert W. Leasure Jr. CEO
NASDAQ (CM) Exchange
45783Q100 CUSIP
US Country
1,945 Employees
- Last Dividend
- Last Split
25 Nov 1997 IPO Date

Overview

Inotiv, Inc. is a prominent provider of nonclinical and analytical drug discovery and development services catering to the pharmaceutical and medical device industries. With a comprehensive approach divided into two main segments: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS), Inotiv's extensive offerings support the entire lifecycle of drug and device development. Originating as Bioanalytical Systems, Inc., the company underwent a rebranding in March 2021 to better reflect its broadened scope and capabilities. Established in 1974 and based in West Lafayette, Indiana, Inotiv has expanded its footprint to include operations in the United States, the Netherlands, and various international locations, ensuring a global reach in its service provision.

Products and Services

  • Research and Discovery Services

    Including computational toxicology, disease pharmacology, DMPK (Drug Metabolism and Pharmacokinetics), safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device services, and cell and molecular biology. These services are crucial for identifying and validating new drug targets, understanding the pharmacokinetic profiles of compounds, and evaluating their safety and efficacy.

  • Non-clinical Safety Assessment

    Comprehensive assessments covering general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and developmental and reproductive toxicology. These assessments are essential for determining the safety profile of new compounds and supporting regulatory submissions.

  • Pathology Services

    Offering histology, digital, clinical, and medical device pathology services. Such services provide crucial information on the effects of drug compounds on body tissues, helping to elucidate mechanisms of action and identify potential adverse effects.

  • Bioanalysis

    Including non-regulated discovery bioanalysis, biotherapeutics characterization, and regulated preclinical and clinical bioanalysis. Bioanalytical services are vital for quantifying drugs and their metabolites in biological samples, supporting the development and validation of bioanalytical methods.

  • Proteomics

    This service involves the large-scale study of proteins, including their expression, functions, and structures, which is integral to understanding disease mechanisms and identifying potential therapeutic targets.

  • Consulting Services

    Providing expert advice on a range of topics, including regulatory strategy, drug development planning, and scientific and technical guidance. These services are crucial for navigating the complex regulatory landscape and ensuring the efficient progression of drugs through the development pipeline.

  • Model and Research Services

    Engages in the commercial production and sales of research models, diets, bedding, and bioproducts. These services support the research community with high-quality models and products necessary for conducting preclinical research.

Contact Information

Address: 2701 Kent Avenue
Phone: 765 463 4527